Drilldown: Medicines

3-MMC (1) · Butorphanol (1) · Butylone (1) · Cathinone (1) · Codeine (2) · Dextropropoxyphene (1) · Dihydrocodeine (1) · Ephylone (1) · Ethcathinone (1) · Ethylmorphine (1) · Ethylone (1) · Fentanyl (1) · Hexedrone (1) · Hydrocodone (1) · Hydromorphone (1) · Lactated Ringer's solution (1) · Levorphanol (1) · Meperidine (1) · Mephedrone (1) · Methcathinone (1) · Methylone (1) · Mexedrone (1) · N-Ethylhexedrone (1) · N-Ethylpentedrone (1) · Nalbuphine (1) · Oxymorphone (1) · Papaverine (1) · Pentazocine (1) · Pentedrone (1) · Sodium chloride (1) · Tapentadol (1)

None (19) · (multiple, generic dominant) (1) · Darvon (1) · Demerol (1) · Dilaudid (1) · Duragesic (1) · Lactated Ringer's Injection (Baxter, B. Braun, ICU Medical); Hartmann's solution (intl.) (1) · Normal saline, NaCl injection, many; nebulized: HyperSal, PulmoSal (1) · Nubain (1) · Nucynta (1) · Opana (1) · Stadol (1) · Talwin (1) · Vicodin (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

Cathinone analogue; monoamine reuptake inhibitor (2) · Kappa agonist; mu antagonist (1) · Kappa agonist; mu partial agonist (1) · Kappa agonist; mu partial agonist/antagonist (1) · Monoamine releasing agent (4) · Monoamine releasing agent; active ingredient in khat (1) · Mu-opioid agonist; norepinephrine reuptake inhibitor (1) · Mu-opioid receptor agonist (4) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Mu-opioid receptor agonist; sodium channel blocker (1) · Mu/kappa/delta agonist; NMDA antagonist (1) · Norepinephrine and dopamine releasing agent (1) · Norepinephrine/dopamine releasing agent (1) · Norepinephrine/dopamine reuptake inhibitor (1) · Phosphodiesterase inhibitor; calcium channel blocker (1) · Potent mu-opioid receptor agonist (3) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) · Serotonin releasing agent; monoamine reuptake inhibitor (1) · Serotonin/norepinephrine/dopamine releasing agent (3) · '"`UNIQ--vote-00000037-QINU`"' Hypertonic 3% is the standard urgent treatment of severely symptomatic hyponatremia'"`UNIQ--ref-00000038-QINU`"'. (1) · '"`UNIQ--vote-00000086-QINU`"' Calcium content is a relative contraindication for co-administration with citrated blood products through the same line'"`UNIQ--ref-00000087-QINU`"'. (1)

None (29) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-00000039-QINU`"', '"`UNIQ--vote-0000003A-QINU`"', '"`UNIQ--vote-0000003B-QINU`"', '"`UNIQ--vote-0000003C-QINU`"', '"`UNIQ--vote-0000003D-QINU`"' (1) · '"`UNIQ--vote-00000088-QINU`"', '"`UNIQ--vote-00000089-QINU`"', '"`UNIQ--vote-0000008A-QINU`"', '"`UNIQ--vote-0000008B-QINU`"' (1)

None (29) · Adult: 15–60 mg every 4 hours as needed. (1) · Volume and concentration titrated to clinical status; symptomatic hyponatremia: 3% NaCl 100-150 mL bolus, reassess (1) · Volume titrated to clinical status; typical adult bolus 500-1000 mL, then reassess (1)

None (29) · 0.225%, 0.45%, 0.9%, 3%, 5% IV solutions; 0.9% nasal spray; 3% and 7% nebulizer solutions; oral tablets (1 g) (1) · 250, 500, 1000 mL IV bags. Composition per liter: Na+ 130 mEq, K+ 4 mEq, Ca2+ 3 mEq, Cl- 109 mEq, lactate 28 mEq (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (29) · 360 mg/day (1) · No fixed maximum; titrated to clinical endpoints (1) · No fixed maximum; titrated; sodium correction rate in chronic hyponatremia must not exceed 8-10 mEq/L per 24 hours to avoid osmotic demyelination (1)

None (29) · intranasal (1) · IV (2) · nebulized (1) · ophthalmic (1) · oral (1) · PO (only formulation marketed in the US). (1)

None (29) · 30–60 min (PO) (1) · Immediate (IV) (1) · Immediate intravascular expansion (1)

None (29) · 4–6 hours (1) · Roughly 20-25% of an IV bolus remains intravascular at 1 hour (1) · Roughly 20-30% remains intravascular at 1 hour (1)

None (29) · 2.5–3 hours (1) · Not applicable (electrolyte solution) (1) · Not applicable (electrolyte) (1)

None (29) · 100% (IV) (1) · 100% (IV); essentially complete (oral) (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (29) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Standard fluid and electrolyte management (1) · Standard resuscitation fluid in pregnancy (1)

None (29) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Prescription only|Rx-only]] for parenteral formulations; OTC for oral, nasal, and many nebulizer products (1) · [[USLegal:Prescription only|Rx-only]] in US (1)